Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.
about
Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host diseaseGlutathione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation.Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia.Unrelated donor transplantation for acute myelogenous leukemia in first remissionAcute graft-versus-host disease: more than just alloreactivity.Nonmyeloablative conditioning with busulfan before matched littermate bone marrow transplantation results in reversal of the disease phenotype in canine leukocyte adhesion deficiency.Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.Busulfan in hematopoietic stem cell transplantationClofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALLInterstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation.Pharmacokinetics of high-dose chemotherapy.Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era.Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive diseasHematopoietic stem cell transplantation for homozygous β-thalassemia and β-thalassemia/hemoglobin E patients from haploidentical donors.A simple dosing scheme for intravenous busulfan based on retrospective population pharmacokinetic analysis in korean patientsPhase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients.Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patientsTherapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide.Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.Safety of conditioning agents for allogeneic haematopoietic transplantation.Busulfan in hematopoietic stem cell transplant setting.Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.Once daily busulfan cyclophosphamide is well tolerated and effective as a preparative regimen for allogeneic hematopoietic stem cell transplant.Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials.Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan.Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission.Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter?Personalizing chemotherapy dosing using pharmacological methods.Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results.Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients.Clinical comparison of weight- and age-based strategy of dose administration in children receiving intravenous busulfan for hematopoietic stem cell transplantation.The role of bacteria and pattern recognition receptors in GVHDDosing algorithm revisit for busulfan following IV infusion.An LC-MS Assay with Isocratic Separation and On-line Solid Phase Extraction to Improve the Routine Therapeutic Drug Monitoring of Busulfan in Plasma.Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.
P2860
Q28299731-7D76FACB-D96B-4A81-9C8D-97D001136C02Q33558113-6F04F0EA-3EC4-463A-8208-A2CA0995F096Q33652742-CBF58989-7FFF-43AF-8F16-DEBE9C0D66C4Q33680218-686E1639-86C3-4E2A-9F1A-E018A2E8F0CAQ33841417-278A097F-E386-4BBF-AFEF-AB2890B81AEFQ33886862-E4F05A5D-5C9F-4C97-BB68-0721A4836B7CQ34314268-6708FF96-87EF-4730-B763-08F277A3AB12Q34409335-701DA4FB-DF63-4492-8D3A-995F0BE12E22Q34505185-CFF7967E-F664-4EDC-8337-C23C844768BEQ34667853-74669AAA-ADE6-40DA-AB76-D10DFF755490Q34668052-BC9AF5E3-1331-4958-99EA-27926448BB97Q35057041-9CECBE9D-5AE9-4424-A504-8E29EA0A7AA6Q35136563-582E36BF-B671-4DF3-AB00-BE721A849E03Q35136616-81811B41-28F9-425B-8034-F96FAC51DFB1Q35486314-86BE450E-EDBA-45DA-86EE-E1B92A04FE20Q35597047-0A37AD8C-6763-4A0A-A9B0-FCE4825CEAE1Q35633858-8312D3A5-B1C4-4B98-A44C-122E5C3EB3C8Q35770722-5E154729-905A-4FF6-90FC-C453EECEE132Q35924098-FEBB2A82-DB9C-444B-9E68-AB1496D625C2Q36166109-240C9860-5DF9-4FD1-8391-9088DCDB623CQ36264692-24E2DEB9-99DC-4BB6-AB5E-C0D216274C69Q36650481-8FA2E701-8DBE-4069-AA38-FE0B86BF6054Q36703516-B9986F3F-067F-4C31-B8D6-59C319FBB6C4Q37140698-70D542D2-A1E5-4C2A-9128-D8CE5EC08BDDQ37510948-A22B0F2A-94E6-431D-89FE-D6D6D21E2B94Q37554387-0A6017AA-A40F-4030-8ECA-C5B5111CF178Q37738997-BC8E78B2-43AD-4E08-9D63-6B4EC2A60174Q37828009-E0DF9DF4-C566-4D2C-8B2E-773CA3D579CCQ37841138-ACA77939-38AC-48CB-A598-27717892FC59Q38060264-9F3007D0-EA30-493A-9A79-5DF03B555FC3Q38133244-F00415BC-9745-4DDA-90A6-8F033982E898Q38225489-2B180491-019E-4CFF-B82A-1A8773ECA7B0Q38571728-2175F8B6-338D-47E2-BFC4-79D8FE6B58EAQ39212390-11E3D88D-798D-4EDA-B3E5-90518A9E7191Q39490930-06F83CE6-7EB4-40F1-A82E-60116CC657A5Q40170434-BBDA5E1B-C478-4B85-85C8-27D3AC1F0CBFQ41218452-72CA64CE-E789-4A11-970D-ED6D87601989Q41621632-DF82BB1F-A243-4E30-A38F-D687DD6A5AF1Q42201727-D08CD80A-F098-472D-B19D-5BB9458982E5Q42351682-FC271A02-F5C2-4203-8AF2-F9531B52383F
P2860
Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Busulfan systemic exposure rel ...... chronic myelogenous leukemia.
@en
type
label
Busulfan systemic exposure rel ...... chronic myelogenous leukemia.
@en
prefLabel
Busulfan systemic exposure rel ...... chronic myelogenous leukemia.
@en
P2093
P1476
Busulfan systemic exposure rel ...... chronic myelogenous leukemia.
@en
P2093
Borje S Andersson
Daniel Couriel
Hai T Tran
James Gajewski
Marcos de Lima
Paolo Anderlini
Peter F Thall
Richard E Champlin
Timothy Madden
Xuemei Wang
P304
P356
10.1053/BBMT.2002.V8.PM12374452
P577
2002-01-01T00:00:00Z